The difference in the results reported could be due to distinctly different patient populations: while previous studies [31,32,33,34,35] did not take into account the IDH mutation status of the participants, IDH mutation was present in 59.1% of our patients, this being a high proportion compared to usual rates in glioma patients. Here, IDH1 is linked to glioma.